Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Atara Biotherapeutics Hold Rating Based on Promising Preclinical Data and Awaited Clinical Trials
Stifel Nicolaus Sticks to Its Hold Rating for Atara Biotherapeutics (ATRA)
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Atara Biotherapeutics: A Balanced Hold Amidst FDA Approval Prospects and Valuation Uncertainties
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.